Lung function modulation

Lung function modulation" refers to any molecular or cellular mechanisms that influence the physiological performance of the lung, including airflow, gas exchange, and tissue integrity. It is not a molecule, receptor, enzyme, or defined protein, but a broad term encapsulating all underlying biological processes and relevant targets (such as ion channels, receptors, transcription factors, enzymes, and structural proteins) involved in lung development, homeostasis, injury response, fibrosis, inflammation, and repair[2][5][1][6]. Key contextual points: - Several **molecular targets** have been identified that play critical roles in lung function, such as: - **Receptors**: Toll-like receptors (TLRs), prostaglandin E2 receptor (PTGER), integrin αvβ3[2][3][5] - **Transcription factors**: NF-κB, KLF9, NRF1, IRF4, EZH2, ATF1[2][1] - **Enzymes/proteins**: Matrix metalloproteinases (MMPs), cyclooxygenase 2 (COX-2), heme oxygenase 1 (HO-1), CYP1B1[2][4][5] - **Growth factors**: TGF-β1, vascular endothelial growth factor (VEGF)[5] - **Immune mediators**: Interleukins (IL6, IL1B), PTX3, GM-CSF[4][2] - **Therapeutic approaches targeting lung function modulation** generally focus on modulating inflammation, fibrosis, tissue remodeling, oxidative stress, and epithelial/immune cell responses[2][5][1][3]. - **Drugs commonly discussed or used in lung function modulation** include nintedanib, pirfenidone, prostaglandin analogs (misoprostol, iloprost), integrin inhibitors, and selective MMP inhibitors—not one single agent[1][3][5]. - **Biomarkers**: PTX3, CYP1B1, CRP, IL-6 levels have been examined as biomarkers for monitoring lung inflammation, response, or injury[4]. - **Safety concerns** vary by drug/class but may include immunosuppression, increased risk of infection, off-target tissue remodeling, and adverse cardiovascular effects[5]. - **Description**: The term "lung function modulation" should be replaced with a specific molecular target for structured data extraction. For instance, describing the "Prostaglandin E2 receptor EP4" or "Transforming growth factor beta 1" provides the necessary specificity for therapeutic and mechanistic insights[3][1][5]. In summary, "lung function modulation" is not a specific target, molecule, or receptor; precise molecular targets or pathways should be specified for structured or drug discovery entries.

Therapeutic approaches generally focus on modulating inflammation, fibrosis, tissue remodeling, oxidative stress, and epithelial/immune cell responses.